Cipher Pharmaceuticals Inc. (CPHRF)
| Market Cap | 153.02M |
| Revenue (ttm) | 22.25M |
| Net Income (ttm) | 22.68M |
| Shares Out | 24.02M |
| EPS (ttm) | 0.92 |
| PE Ratio | 6.92 |
| Forward PE | 18.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,765 |
| Open | 6.43 |
| Previous Close | 6.46 |
| Day's Range | 6.37 - 6.46 |
| 52-Week Range | 2.50 - 7.45 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 4.75 (-25.43%) |
| Earnings Date | n/a |
About CPHRF
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwante... [Read more]
Full Company ProfileFinancial Performance
In 2023, CPHRF's revenue was $21.55 million, an increase of 4.23% compared to the previous year's $20.68 million. Earnings were $20.38 million, a decrease of -23.48%.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to one analyst, the rating for CPHRF stock is "Buy" and the 12-month stock price forecast is $4.75.
News
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Mississauga, Ontario--(Newsfile Corp. - April 3, 2024) - Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which wil...